PEG

MS-39 stands out as a powerful, highly selective Degrader (PROTAC) specifically designed for mutant epidermal growth factor receptor (EGFR). This innovative compound features gefitinib linked to a VHL ligand through a linker, showcasing exceptional potency and high affinity.

SIAIS178 represents an innovative proteolysis-targeting chimeric (PROTAC) degrader—a unique hybrid molecule intertwining the BCR-ABL kinase inhibitor dasatinib with a ligand designed for the Von Hippel-Lindau (VHL) E3 ubiquitin ligase through an optimized linker. It effectively directs the BCR-ABL protein for degradation through VHL-mediated mechanisms.

CPS2, a pioneering compound, is a potent, selective, and irreversible PROTAC CDK2 degrader, marking a significant advancement in this class of molecules. This innovative agent, CPS2, holds promise for research applications in the study of acute myeloid leukemia.

PROTAC RIPK degrader-6 is a Cereblon-based molecular agent developed to target the degradation of RIP Kinase. Within its structure, a RIP2 kinase inhibitor is intricately linked to a cereblon binder through a specialized linker.

MD-224 is a novel PROTAC-based small molecule designed to specifically degrade the MDM2 proto-oncogene. As a pioneering and highly effective degrader, MD-224 represents a new class of anticancer agents with significant potential in targeted therapy. Functioning as a click chemistry reagent, it harbors an alkyne group, enabling it to engage in copper-catalyzed azide-alkyne cycloaddition (CuAAC) with molecules featuring Azide groups.

INY-03-041 emerges as a potent and highly selective pan-AKT degrader utilizing the PROTAC approach. This compound comprises the ATP-competitive AKT inhibitor Ipatasertib linked to Lenalidomide. With its inhibitory action, INY-03-041 effectively targets and suppresses AKT1, AKT2, and AKT3.

SD-36, a potent and selective STAT3 degrader, induces complete degradation of the STAT3 protein in both xenograft tumor tissue and normal mouse tissues upon a single dose administration. SD-36 establishes itself as a powerful and effective solution for STAT3 degradation.

QCA570 stands out as an exceptionally potent and effective Proteolysis Targeting Chimera (PROTAC) degrader specifically designed for the Bromodomain and Extra-Terminal (BET) proteins. It not only demonstrates remarkable potency but also exhibits the capability to induce complete and enduring tumor regression.

SNIPER(ER)-87 stands out as a powerful and targeted degrader of estrogen receptor α (ERα), functioning as a Specific and Nongenetic IAP-dependent Protein Eraser (SNIPER). This compound is composed of the IAP binding ligand LCL 161, connected by a linker to the estrogen-binding component, 4-hydroxytamoxifen.